Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1995, and the nine-month period ended March 31, 1995, for Lectec Corporation (not Axogen, Inc., as indicated in the metadata). The company manufactures conductive products, medical tapes, and therapeutic products. The financial statements consolidate the results of Natus Corporation, a 51% owned subsidiary, effective April 1, 1994.
Key Financial Metrics
| Metric | Q3 1995 | Q3 1994 | 9 Months 1995 | 9 Months 1994 |
|---|---|---|---|---|
| Total Revenues | $4,232,402 | $2,252,783 | $10,822,734 | $7,864,822 |
| Gross Profit | $1,734,732 | $762,611 | $4,387,588 | $2,987,917 |
| Gross Margin % | 41.0% | 33.9% | 40.5% | 38.0% |
| Operating Profit | $251,187 | ($5,237) | $341,501 | $772,567 |
| Net Earnings | $184,543 | $19,485 | $302,810 | $509,853 |
| EPS (Diluted) | $0.05 | $0.01 | $0.08 | $0.13 |
| Cash and Equivalents | $748,778 | N/A | N/A | N/A |
| Working Capital | $4,401,270 | $5,957,622 | N/A | N/A |
| Current Ratio | 3.79 | 7.45 | N/A | N/A |
Debt and Liquidity: The company reported no long-term debt. It maintains an unused $1,000,000 line of credit. Net cash used in operating activities for the nine months ended March 31, 1995, was $149,941, compared to net cash provided of $46,433 in the prior year period.
Material Changes Versus Prior Period
- Revenue Growth: Product sales increased 87.9% in Q3 1995 and 37.9% for the nine-month period compared to the prior year. This growth was driven by the consolidation of Natus Corporation and significant increases in medical tape (101.1%) and therapeutic product sales (382.8%).
- Profitability: Operating profit improved significantly in Q3 1995 ($251,187) compared to a loss in Q3 1994. However, for the nine-month period, earnings before taxes decreased from $887,610 to $407,198 due to reduced margins on medical tape and increased operating expenses.
- Expenses: Selling, general, and administrative (SG&A) expenses rose as a percentage of revenue (24.4% in Q3 1995 vs. 18.6% in Q3 1994) due to Natus consolidation and goodwill amortization. R&D expenses increased in absolute terms but decreased as a percentage of revenue.
- Liquidity: Working capital decreased by approximately $1.56 million, and the current ratio declined from 7.45 to 3.79, reflecting increased receivables and inventory to support growth.
Guidance, Outlook, and Risks
- R&D Outlook: Management anticipates R&D expenses will continue in the range of 10% to 15% of revenues. The company is aggressively developing a non-nicotine smoking cessation product, having completed Phase II clinical trials with positive efficacy results in April 1995.
- Strategic Shift: Following McNeil Consumer Products' decision not to exercise its licensing option in December 1994, Lectec retained maximum rights to the smoking cessation product and plans to seek new marketing alliances.
- Capital Expenditures: The company estimates capital expenditures will exceed $1,300,000 for fiscal 1995 to support new production lines.
- Risks: The filing notes that interim results are not necessarily indicative of full-year results. The company relies on internally generated cash and a line of credit for liquidity.
Key Facts for Investor Verification
- Verify the sustainability of the 382.8% increase in therapeutic product sales driven by Natus Corporation.
- Confirm the timeline and commercialization strategy for the non-nicotine smoking cessation product following the completion of Phase II trials.
- Monitor the trend in working capital and the current ratio, which have declined significantly due to inventory and receivable build-up.
- Assess the impact of goodwill amortization and increased SG&A expenses on future operating margins.
- Review the status of the $1,000,000 line of credit and the company's ability to fund the projected $1.3 million in capital expenditures without external financing.